<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166462">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930735</url>
  </required_header>
  <id_info>
    <org_study_id>09/0904</org_study_id>
    <nct_id>NCT00930735</nct_id>
  </id_info>
  <brief_title>The Prognostic Significance of Fibrosis Detection in Cardiomyopathy</brief_title>
  <official_title>The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems
      and lead to the developement of heart failure

      Clinical significance Correlation with biomarkers and genetic markers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left
      ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where
      appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion
      using pharmacological stress imaging (contraindications to include comorbidities that do not
      permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic
      stenosis)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular arrhythmias</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unplanned heart failure admissions</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA status</measure>
    <time_frame>3</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Myocardial fibrosis, outcomes</arm_group_label>
    <description>Groups with none and variable amounts of myocardial fibrosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma and myocardium
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive referrals for CMR from tertiary and nontertiary referral hospitals scanned to
        evaluate presence and amount of myocardial scarring.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of an ischaemic or non-ischaemic cardiomyopathic process

          -  no contraindication to contrast enhanced CMR

          -  GFR &gt;30

        Exclusion Criteria:

          -  ESRF

          -  Contraindication to CM R
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay K Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton and Harefield Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 5, 2015</lastchanged_date>
  <firstreceived_date>June 27, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Sanjay Prasad</investigator_full_name>
    <investigator_title>Consultant Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
